Rate My Professor Laurence Cheung

Cheung's research centers on the bone marrow microenvironment in childhood leukaemia, with emphasis on high-risk subtypes including KMT2A-rearranged infant acute lymphoblastic leukaemia, Down syndrome-associated leukaemia, and mechanisms of therapy resistance. His investigations explore age-dependent drug targets, preclinical patient-derived models, novel inhibitors such as NAMPT inhibitor OT-82 combined with venetoclax, menin inhibitors, sclerostin inhibition for bone protection, and the role of osteoclasts in leukaemia progression and immune regulation. He has published over 66 peer-reviewed articles, including recent works such as 'Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL' (Blood Advances, 2026), 'Targeting nicotinamide metabolism with NAMPT-inhibitor OT-82 potentiates venetoclax in preclinical models of pediatric and adult acute myeloid leukemia' (Cancer Research, 2026), 'Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction' (HemaSphere, 2026), 'Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia' (Leukemia & Lymphoma, 2026), and 'Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia' (Cancer and Metastasis Reviews, 2025). Cheung has attracted over $8.7 million in competitive research funding, including $591,277 from the WA Child Research Fund for the CHILD BMM project aimed at combating high-risk childhood leukaemia through microenvironment dissection (2024/25), and support from the Channel 7 Telethon Trust.